These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 25758918)

  • 1. Trapping Poly(ADP-Ribose) Polymerase.
    Shen Y; Aoyagi-Scharber M; Wang B
    J Pharmacol Exp Ther; 2015 Jun; 353(3):446-57. PubMed ID: 25758918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
    Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
    Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
    Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
    Murai J; Huang SY; Das BB; Renaud A; Zhang Y; Doroshow JH; Ji J; Takeda S; Pommier Y
    Cancer Res; 2012 Nov; 72(21):5588-99. PubMed ID: 23118055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast.
    Perkins E; Sun D; Nguyen A; Tulac S; Francesco M; Tavana H; Nguyen H; Tugendreich S; Barthmaier P; Couto J; Yeh E; Thode S; Jarnagin K; Jain A; Morgans D; Melese T
    Cancer Res; 2001 May; 61(10):4175-83. PubMed ID: 11358842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
    Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
    J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG; Patel BD
    Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity.
    Kuo ML; Shen SC; Yang CH; Chuang SE; Cheng AL; Huang TS
    Oncogene; 1998 Oct; 17(17):2225-34. PubMed ID: 9811453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
    Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
    Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside.
    Plummer R
    Clin Oncol (R Coll Radiol); 2014 May; 26(5):250-6. PubMed ID: 24602564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
    Wang B; Qian H; Yiu SM; Sun J; Zhu G
    Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.